(Q54358422)

28 May 2018

title

Sulfonylureas or dipeptidyl peptidase (DPP-4) inhibitors in the management of type 2 diabetes: debate is not yet closed. (English)

1 reference

28 May 2018

1 reference

Pierre-Jean Guillausseau

series ordinal

1

1 reference

28 May 2018

publication date

1 December 2011

1 reference

28 May 2018

published in

Current diabetes report

1 reference

28 May 2018

volume

11

1 reference

28 May 2018

issue

6

1 reference

28 May 2018

page(s)

461-2; author reply 463

1 reference

28 May 2018

https://scigraph.springernature.com/pub.10.1007/s11892-011-0227-6

exact match

0 references

cites work

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS11892-011-0227-6

Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-011-0227-6

The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-011-0227-6

Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-011-0227-6

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-011-0227-6

UKPDS and the legacy effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-011-0227-6

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-011-0227-6

Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-011-0227-6

Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes?

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21915770

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11892-011-0227-6

1 reference

28 May 2018

1 reference

28 May 2018